Reduce your recruitment timelines

Using our efficient recruitment techniques, adaptive study designs and integrated protocols we can run hybrid studies reducing our sponsors’ drug development time.

Examples of our accelerated recruitment

Accurate costs projection. We conducted a FIH study of Lumasiran in March 2016. Our team helped to accelerate drug development using adaptive study design and provide accurate cost projections through efficient recruitment. Alnylam received marketing authorisation in April 2020.

In a study for Symptomatic Transthyretin Amyloid Cardiomyopathy, Richmond Pharmacology enrolled 11% of patients in a multi-centre study involving 104 global centres.

Reliability and operational scalability. Our in-house recruitment team enrolled 92 hypertensive patients for a global study on behalf of Alnylam, fulfilling 58% of the total cohort. Our patient networks enabled us to rapidly upscale recruitment and reduce the study timelines.

x

We enable rapid drug development

By swiftly adapting strategies to suit the unique demands of individual trials, we ensure resources are invested in the most appropriate recruitment tactics. Frequently recruiting more than our allotted cohort size in multi-centre studies, we enable our sponsors to complete enrolment early.

We are renowned for our recruitment capabilities.

Our dedicated in-house recruitment team delivers a personal service ensuring volunteers are engaged from the first contact to the last appointment.

Get in touch today

Why choose Richmond Pharmacology for Patient Recruitment in Early Phase Studies

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Strategic and efficient

You will experience a truly personal service.

Read more +

Diverse patient database

Our recruitment database is arguably the largest in Europe.

Read more +

Accurate timeline and cost predictability

We offer invaluable insight into study acceptability and suitability.

Read more +

Volunteer experience

By listening to the feedback of our volunteers, we make continuous improvements to the experience of our research participants.

Read more +

We enrol more patients safely to your study in a shorter time span using our streamlined procedures

Latest news

Futureproofing early phase clinical research for the next generation of investigators.

March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read more

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Events

13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event